UBS Forecasts 10% Revenue Growth for Healthcare Sector This Year, Names 3SBIO as Top Pick

Stock News

昨天

UBS has released a research report projecting that the median revenue growth for rated healthcare companies will reach 16% in 2025 and 10% in 2026, based on the latest industry sales data and licensing transactions. The bank expects most companies' core product sales to meet or exceed its forecasts. UBS has replaced HANSOH PHARMA with 3SBIO as its top pick, assigning 3SBIO a "buy" rating and a target price of HK$41, citing reasonable valuation. Looking ahead to 2026, the bank anticipates median sector revenue growth of 10%, supported by steady sales growth of innovative drugs and promising R&D progress. UBS also raised target prices for several stocks: CSPC PHARMA's target was increased from HK$10 to HK$10.9, HANSOH PHARMA's from HK$48.2 to HK$51.5, and HENGRUI PHARMA's from HK$96.9 to HK$98.3. The respective ratings assigned are "neutral," "buy," and "buy."

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1148570608"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148570608\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148570608?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 14:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148570608","market":"nz","top_or_hot":-1,"title":"UBS Forecasts 10% Revenue Growth for Healthcare Sector This Year, Names 3SBIO as Top Pick","media":"Stock News","content":"<p>UBS has released a research report projecting that the median revenue growth for rated healthcare companies will reach 16% in 2025 and 10% in 2026, based on the latest industry sales data and licensing transactions. The bank expects most companies' core product sales to meet or exceed its forecasts. UBS has replaced HANSOH PHARMA with 3SBIO as its top pick, assigning 3SBIO a \"buy\" rating and a target price of HK$41, citing reasonable valuation. Looking ahead to 2026, the bank anticipates median sector revenue growth of 10%, supported by steady sales growth of innovative drugs and promising R&D progress. UBS also raised target prices for several stocks: CSPC PHARMA's target was increased from HK$10 to HK$10.9, HANSOH PHARMA's from HK$48.2 to HK$51.5, and HENGRUI PHARMA's from HK$96.9 to HK$98.3. The respective ratings assigned are \"neutral,\" \"buy,\" and \"buy.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Forecasts 10% Revenue Growth for Healthcare Sector This Year, Names 3SBIO as Top Pick</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Forecasts 10% Revenue Growth for Healthcare Sector This Year, Names 3SBIO as Top Pick\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-02 14:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS has released a research report projecting that the median revenue growth for rated healthcare companies will reach 16% in 2025 and 10% in 2026, based on the latest industry sales data and licensing transactions. The bank expects most companies' core product sales to meet or exceed its forecasts. UBS has replaced HANSOH PHARMA with 3SBIO as its top pick, assigning 3SBIO a \"buy\" rating and a target price of HK$41, citing reasonable valuation. Looking ahead to 2026, the bank anticipates median sector revenue growth of 10%, supported by steady sales growth of innovative drugs and promising R&D progress. UBS also raised target prices for several stocks: CSPC PHARMA's target was increased from HK$10 to HK$10.9, HANSOH PHARMA's from HK$48.2 to HK$51.5, and HENGRUI PHARMA's from HK$96.9 to HK$98.3. The respective ratings assigned are \"neutral,\" \"buy,\" and \"buy.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B543WZ88.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1148570608","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148570608","pubTimestamp":1772431669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UBS has released a research report projecting that the median revenue growth for rated healthcare companies will reach 16% in 2025 and 10% in 2026, based on the latest industry sales data and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159760":"医疗健康","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","01276":"恒瑞医药","BK1515":"抗疫概念","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","XLV":"健康照护类股ETF-SPDR","BK1583":"高瓴概念","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1521":"挪威政府全球养老基金持仓","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LABU":"三倍做多标普生物-Direxion","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","BK1589":"北水核心资产","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK4588":"碎股","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","01530":"三生制药","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","03692":"翰森制药","XBI":"SPDR S&P Biotech ETF","01093":"石药集团","LU0359201612.USD":"贝莱德中国基金A2","BK1191":"制药","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","BK1593":"医美概念股","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","BK1161":"生物科技","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC"},"translate_title":"瑞银预测今年医疗保健行业收入增长10%，三生制药为首选","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159760":1,"01276":1,"03692":1,"LABU":1,"01093":1,"XLV":1,"01530":1,"XBI":1},"content_text":"UBS has released a research report projecting that the median revenue growth for rated healthcare companies will reach 16% in 2025 and 10% in 2026, based on the latest industry sales data and licensing transactions. The bank expects most companies' core product sales to meet or exceed its forecasts. UBS has replaced HANSOH PHARMA with 3SBIO as its top pick, assigning 3SBIO a \"buy\" rating and a target price of HK$41, citing reasonable valuation. Looking ahead to 2026, the bank anticipates median sector revenue growth of 10%, supported by steady sales growth of innovative drugs and promising R&D progress. UBS also raised target prices for several stocks: CSPC PHARMA's target was increased from HK$10 to HK$10.9, HANSOH PHARMA's from HK$48.2 to HK$51.5, and HENGRUI PHARMA's from HK$96.9 to HK$98.3. The respective ratings assigned are \"neutral,\" \"buy,\" and \"buy.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}